Option Investor
Newsletter

WATCH LIST SEPTEMBER - CELG GAINS APPROVAL FROM ADVISORY FOR NEW DRUG

HAVING TROUBLE PRINTING?
Printer friendly version

WATCH LIST UPDATE - CELG DRUG GAINS APPROVAL FROM ADVISORY

US ADVISORY PANEL SUPPORTS CELGENE'S ANEMIA DRUG REVLIMID

US panel supports Celgene anemia drug Revlimid

Wed Sep 14, 2005 12:04 PM ET
BETHESDA, Md., Sept 14 (Reuters) -


A U.S. advisory panel on Wednesday voted 10-5 to recommend approval
of Celgene Corp.'s Revlimid to treat anemia in patients with potentially
fatal blood disorders known as myelodysplastic syndromes.
The drug is a new version of Celgene's Thalomid or thalidomide,
and aims to be safer with fewer side effects.

The Food and Drug Administration will make the final decision but
usually heeds the advice of its advisory panels.

We will advise, if necessary when stock reopens for trading.


Monthly Cash Machine Newsletter Archives